富祥药业
(300497)
| 流通市值：52.21亿 | | | 总市值：63.58亿 |
| 流通股本：4.52亿 | | | 总股本：5.50亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 976,875,468.35 | 682,414,380.47 | 340,430,593.83 | 1,609,669,988.35 |
| 营业收入 | 976,875,468.35 | 682,414,380.47 | 340,430,593.83 | 1,609,669,988.35 |
| 二、营业总成本 | 1,077,531,750.26 | 735,159,855.02 | 347,981,386.08 | 1,774,266,424.72 |
| 营业成本 | 880,028,133.92 | 611,470,146.94 | 288,911,075.19 | 1,438,617,314.54 |
| 税金及附加 | 12,627,267.45 | 8,569,529.32 | 4,783,074.12 | 16,655,502.64 |
| 销售费用 | 12,646,119.93 | 7,895,702.05 | 2,355,625.15 | 35,339,962.94 |
| 管理费用 | 94,661,815.6 | 59,999,349.67 | 29,328,497.65 | 160,316,255.15 |
| 研发费用 | 54,877,753.79 | 34,728,290.23 | 15,874,928.96 | 97,453,168.04 |
| 财务费用 | 22,690,659.57 | 12,496,836.81 | 6,728,185.01 | 25,884,221.41 |
| 其中:利息费用 | 30,589,566 | 20,739,269.16 | 10,806,535.23 | 42,031,308.69 |
| 其中:利息收入 | 5,474,334.4 | 4,077,482.35 | 2,339,089.02 | 9,294,011.56 |
| 加:公允价值变动收益 | - | 0 | - | 659,373.35 |
| 加:投资收益 | -1,081,409.46 | -1,125,203.98 | 110,650.16 | -16,162,119.6 |
| 资产处置收益 | -104,670.72 | -104,670.72 | - | 76,295.65 |
| 资产减值损失(新) | -764,171.65 | -764,171.65 | - | -51,763,365.01 |
| 信用减值损失(新) | -1,241,930.39 | -2,080,533.29 | -443,849.78 | -4,370,471.18 |
| 其他收益 | 41,017,587.27 | 35,450,005.7 | 11,986,174.24 | 6,767,611.59 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -62,830,876.86 | -21,370,048.49 | 4,102,182.37 | -229,389,111.57 |
| 加:营业外收入 | 383,574.65 | 274,748.86 | 77,134.53 | 918,627.21 |
| 减:营业外支出 | 723,058.89 | 427,482.48 | 350,904.97 | 4,700,395.63 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -63,170,361.1 | -21,522,782.11 | 3,828,411.93 | -233,170,879.99 |
| 减:所得税费用 | 6,037,125.6 | 5,500,797.44 | 4,568,321.44 | -9,914,787.31 |
| 六、净利润 | -69,207,486.7 | -27,023,579.55 | -739,909.51 | -223,256,092.68 |
| 持续经营净利润 | - | -27,023,579.55 | -739,909.51 | -223,256,092.68 |
| 归属于母公司股东的净利润 | -62,074,959.23 | -22,459,249.25 | 1,468,451.11 | -200,800,049.29 |
| 少数股东损益 | -7,132,527.47 | -4,564,330.3 | -2,208,360.62 | -22,456,043.39 |
| (一)基本每股收益 | -0.12 | -0.04 | 0 | -0.37 |
| (二)稀释每股收益 | -0.12 | -0.04 | 0 | -0.37 |
| 八、其他综合收益 | - | - | - | -2,632,231.52 |
| 归属于母公司股东的其他综合收益 | - | - | - | -2,632,231.52 |
| 九、综合收益总额 | -69,207,486.7 | -27,023,579.55 | -739,909.51 | -225,888,324.2 |
| 归属于母公司股东的综合收益总额 | -62,074,959.23 | -22,459,249.25 | 1,468,451.11 | -203,432,280.81 |
| 归属于少数股东的综合收益总额 | -7,132,527.47 | -4,564,330.3 | -2,208,360.62 | -22,456,043.39 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |